Panel Discussion: Identifying the Right Combination for Different Cancers by Tailoring RAS Inhibitors for Tumor-Specific Reponses
- Overcoming the complexity of tumor biology and multiple signaling pathways to select the optimal combination approach for different cancer types
- How can patient-specific genetic profiles and tumor microenvironment data inform the design of more effective combination therapies?
- How do RAS inhibitors alter the tumor microenvironment and improve response to current standard of care cancer treatments?